youtube_live
Q3 2026 earnings • in 1 day
See detailschevron_right
UTHR:NASDAQ
United Therapeutics Corp
$596.13
arrow_downward
-0.43%(-2.59) 1D
$596.13
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UTHR...
Open
$596.54
High
$600.90
Low
$592.46
Mkt. cap
25.57B
Avg. vol.
809.79K
Volume
0.00
P/E ratio
21.32
52-wk high
$609.99
52-wk low
$430.02
EPS
$27.96
Beta
0.49
Shares outstanding
42.89M
No. of employees
1K
Open
$596.54
High
$600.90
Low
$592.46
Mkt. cap
25.57B
Avg. vol.
809.79K
Volume
0.00
P/E ratio
21.32
52-wk high
$609.99
52-wk low
$430.02
EPS
$27.96
Beta
0.49
Shares outstanding
42.89M
No. of employees
1K
News stories
From web sources and news partners
TradingView
·
3 hours ago
United Therapeutics (UTHR) to report earnings tomorrow: here is what to expect
www.marketscreener.com
·
8 hours ago
United Therapeutics Insider Sold Shares Worth $5,700,856, According to a Recent SEC Filing
Benzinga
·
15 hours ago
SpaceX Launch Customer Varda Says a Single Flight Could Help Make Medicine for Millions
Investing.com
·
23 hours ago
United Therapeutics evp Paul Mahon sells $4.1M in UTHR shares
Profile
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire. Wikipedia
About United Therapeutics Corp
CEO-
Employees1.4K
Founded1996
HeadquartersSilver Spring, Maryland, United States
SectorBiotechnology
Websiteunither.com
Analyst ratings
Based on 14 analysts giving stock ratings to UTHR in the past 3 months
Buy
Buy
11
Hold
2
Sell
1
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for UTHR in the last 3 months.
Highest
Current $596.13
$850.00 (+42.59%)
Average
$669.21 (+12.26%)
Lowest
$368.00 (-38.27%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Jessica Fye J.P. Morgan | Buy | Reiterated | $695.00 | +16.6% | 10/28/2026 |
Olivia Brayer Cantor Fitzgerald | Buy | Maintained | $850.00 | +42.6% | 10/26/2026 |
Lisa Walter RBC Capital | Buy | Reiterated | $697.00 | +16.9% | 10/22/2026 |
Tiago Fauth Raymond James | Buy | Maintained | $717.00 | +20.3% | 10/20/2026 |
Roanna Ruiz Leerink Partners | Buy | Reiterated | $725.00 | +21.6% | 10/20/2026 |
Benjamin Burnett Wells Fargo | Buy | Maintained | $700.00 | +17.4% | 10/16/2026 |
Andrea Newkirk Goldman Sachs | Sell | Maintained | $368.00 | -38.3% | 10/15/2026 |
Ashwani Verma UBS | Buy | Maintained | $725.00 | +21.6% | 10/13/2026 |
Jason Gerberry Bank of America Securities | Hold | Reiterated | $559.00 | -6.2% | 10/09/2026 |
Terence Flynn Morgan Stanley | Hold | Maintained | $566.00 | -5.1% | 10/07/2026 |
Roger Song Jefferies | Buy | Maintained | $704.00 | +18.1% | 10/01/2026 |
Julian Harrison BTIG | Buy | Upgraded | $728.00 | +22.1% | 10/01/2026 |
Joseph Thome TD Cowen | Buy | Maintained | $675.00 | +13.2% | 09/02/2026 |
Andrew Fein H.C. Wainwright | Buy | Maintained | $660.00 | +10.7% | 08/06/2026 |
Unknown Analyst J.P. Morgan | Buy | Maintained | $685.00 | +14.9% | 05/20/2026 |
Unknown Analyst Raymond James | Buy | Initiated | $700.00 | +17.4% | 04/09/2026 |
Andreas Argyrides Oppenheimer | Buy | Maintained | $650.00 | +9% | 03/12/2026 |
Jasper Hellweg Argus Research | Buy | Reiterated | $560.00 | -6.1% | 03/03/2026 |
Next call in 31:17:31
Wed, Nov 4, 9:00 AM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $6.36
Revenue / Est. (USD)
- / 781.14M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 799.50M | 790.20M | 781.50M | 783.30M |
Cost of goods sold | 100.90M | 103.40M | 133.40M | 99.50M |
Cost of revenue | 100.90M | 103.40M | 133.40M | 99.50M |
Research and development expenses | 127.50M | 139.50M | 138.20M | 146.30M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 181.80M | 189.90M | 184.10M | 206.70M |
Operating expense | 309.30M | 329.40M | 322.30M | 353.00M |
Total operating expenses | 410.20M | 432.80M | 455.70M | 452.50M |
Operating income | 389.30M | 357.40M | 325.80M | 330.80M |
Other non operating income | 300.00K | 800.00K | 15.30M | -100.00K |
EBT including unusual items | 438.00M | 444.00M | 318.30M | 372.70M |
EBT excluding unusual items | 433.00M | 398.30M | 379.90M | 359.30M |
Income tax expense | 99.30M | 79.70M | 43.40M | 39.70M |
Effective tax rate | 22.67% | 17.95% | 13.63% | 10.65% |
Other operating expenses | - | - | - | - |
Net income | 338.70M | 364.30M | 274.90M | 333.00M |
Net profit margin | 42.36% | 46.10% | 35.18% | 42.51% |
Earnings per share | 7.16 | 7.70 | 5.82 | 7.27 |
Interest and investment income | 46.40M | 43.20M | 41.80M | 31.50M |
Interest expense | -3.00M | -3.10M | -3.00M | -2.90M |
Net interest expenses | 43.40M | 40.10M | 38.80M | 28.60M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 411.20M | 380.20M | 348.40M | 355.00M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events